Nyhet -

Novel treatments for aggressive cancer based on a unique target

The discovery of the unique target integrin α10β1 may change the outcome of cancer treatment for thousands of patients across the world. Tumor-targeting antibodies for the treatment of aggressive cancers are currently being developed by Targinta, a subsidiary of biopharma company Xintela in Lund.

Targinta is the oncology subsidiary of the stem cell company Xintela. Both Xintela and Targinta are focusing on therapies in areas where there is a lack of effective treatment. While Xintela’s focus is on regenerative medicine, aiming to develop novel disease modifying treatments for osteoarthritis and difficult-to-heal venous leg ulcers, Targinta’s focus is on aggressive cancers such as triple-negative breast cancer and the brain cancer glioblastoma.

Unique patented target

Targinta was founded based on the in-house discovery that the cell surface receptor integrin α10β1 is selectively overexpressed on certain very aggressive cancers such as glioblastoma and triple-negative breast cancer, but with very low expression in normal tissues. This allowed for an exceptional patent portfolio that essentially prevents any competitor from developing a competing drug against the target.

Many companies globally are looking for new oncology targets, according to Per Norlén,

“We have a unique and patent-protected target with exclusive rights for drug development. There are several other companies developing toxin-armed antibodies, so called ADCs (antibody-drug conjugates), but almost all of them are restricted to well-known targets without patent protection”, says Per Norlén, CEO of Targinta.

Public listing is in the plans

Targinta is now fully prepared for listing on the stock exchange, and the plan is to do this at First North as soon as possible, which is likely to be immediately after the summer holidays. Per Norlén reveals that the company’s strategy is to develop the drug candidates internally through preclinical development followed by partnerships for continued clinical development and commercialisation.

“The most important aspect of our tumour-targeting antibodies and ADCs is that the selective expression of the target in aggressive cancers allows for stronger effect and lower toxicity. Targinta has emerged as one of the leading Nordic companies developing ADCs, an area that has grown very fast in recent years with several market approvals. With first-in-class drug candidates in a hot area based on a unique and patent-protected target, Targinta’s ambition is to enter into pivotal partnerships to accelerate the development of our new cancer treatment through clinical development and to patients”, Per Norlén concludes.

Relaterade länkar

Ämnen

  • Ekonomi, finans

Kategorier

  • medicon valley life science

Regioner

  • Skåne

Kontakter

Relaterat innehåll

  • The uniqueness of Medicon Valley Alliance

    Medicon Valley Alliance (MVA) is a non-profit membership organisation in the Danish-Swedish life science cluster Medicon Valley. They also have the distinction of being the only bi-national cluster region in the Nordics.
    All cluster formations within Life Science collaborate with other actors nationally and internationally, but MVA has built an entire life science cluster across two leading lif

  • Making the impossible possible

    Diagonal Bio AB (Diagonal) is a biotech company that seeks to do what was once thought impossible – create a universal diagnostic platform which is quick, accurate, cost-effective and able to test multiple samples in parallel. The company was founded in Medicon Village in Lund in 2020, with a vision to limit the spread of infectious disease world-wide.
    Diagonal plan to realise the vision by cr

  • Supporting life science to grow

    Medicon Village is a vibrant and dynamic environment with great development potential. After AstraZeneca, there is still a large supply of expertise in the region, and this has led to many start-ups in the area. There is at the same time a continuing need to attract new talent to Medicon Village and that is why PharmaRelations, combining Nordic coverage with local expertise within Life Science, ha

  • Stem cell product XSTEM in clinical studies

    The Swedish biopharma company Xintela is receiving a lot of attention for its stem cell product platform XSTEMÒand its stem cell therapies in development.
    XSTEM is now in clinical development for the treatment of knee osteoarthritis and difficult-to-heal venous leg ulcers.
    Over the last several years Xintela has worked extensively on preclinical development in three core areas: osteoarthrit

  • Providing a fast lane to preclinical development

    The past year has been very productive at the relatively small Contract Research Organisation (CRO) Redoxis. Being specialised in preclinical drug development and efficacy evaluation models, Redoxis offers invaluable support to any pharmaceutical drug developer at the very early stages.
    “A lot of CROs tend to focus on the later phases of development, even if they still retain a preclinical app

  • The splendour of tolerogenic cell therapies

    The biotech company Idogen develops tolerogenic cell therapies to prevent biological drugs, transplanted organs or the body’s own cells or tissue from being attacked by the patient’s immune system.
    Idogen was founded 2008 in Lund, but is today a public company listed on the Nasdaq First North Growth Market. The company has now entered into a very exciting phase where it’s first clinical trial,

  • New MDR and IVDR provide both challenges and opportunities

    Most pharmaceutical and medical device developers need guidance to come to terms with new and changing regulations. They also need competent hands-on support in times of high workload. Not least, concerning the new regulations of medical technology products, MDR, and the new IVDR for in-vitro diagnostics.
    Pharmaceutical companies, In-Vitro Diagnostic Companies and Medical Device developers are

  • Creating long-term strategic partnerships in the Medicon Valley

    In an ever-evolving world with rapid changes across all sectors and products, understanding and adapting your business and your product has never been more key. Anna Stenstam and the team at CR Competence are at the forefront of this changing pace and are operating right at the heart of Medicon Valley.
    With more than 350 companies, the Medicon Valley has become a bedrock for biotech, medtech an

  • Very promising clinical results in new treatment of varicose veins

    Established in 2013 by Dr Michael Åkesson, the company MedVasc was created to help his pursuit on improving the procedure of minimally invasive treatment in the condition of varicose vein. Michael has a long experience in developing and testing new catheters for endovascular techniques.
    The earning potential of Solutio (which was patented in 2015) paved the way for additional investment and cre